Extended urinary Δ9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure

Drug and Alcohol Dependence

Volumn 105, Issue 1-2, 2009, Pages 24-32

  Lowe, Ross H ^a   Abraham, Tsadik T ^a   Darwin, William D ^a   Herning, Ronald ^a   Cadet, Jean Lud ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Cannabinoids; Cannabis; Chronic cannabis use; Tetrahydrocannabinol; THC; Urine

Indexed keywords

BETA GLUCURONIDASE; BIOCHEMICAL MARKER; CANNABINOID; CANNABIS; DRONABINOL; 11 HYDROXY DELTA(9) TETRAHYDROCANNABINOL; 11-HYDROXY-DELTA(9)-TETRAHYDROCANNABINOL; BIOLOGICAL MARKER; DELTA(9) TETRAHYDROCANNABINOLIC ACID; DELTA(9)-TETRAHYDROCANNABINOLIC ACID; DRUG DERIVATIVE; TETRAHYDROCANNABINOL;

ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DETOXIFICATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC VALUE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LONG TERM EXPOSURE; MALE; MASS SPECTROMETRY; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SMOKING; URINALYSIS; URINARY EXCRETION; VALIDITY; ADDICTION; CHRONIC DISEASE; ETHNIC GROUP; MASS FRAGMENTOGRAPHY; METHODOLOGY; SUBSTANCE ABUSE; URINE;

CANNABIS; ESCHERICHIA COLI;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; ETHNIC GROUPS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MARIJUANA ABUSE; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 70049110345     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.05.027     Document Type: Article

References (30)

1. Abraham T.T., Lowe R.H., Pirnay S.O., Darwin W.D., and Huestis M.A. Simultaneous GC-EI-MS determination of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J. Anal. Toxicol. 31 (2007) 477-485
2. Bolla K.I., Brown K., Eldreth D., Tate K., and Cadet J.L. Dose-related neurocognitive effects of marijuana use. Neurology 59 (2002) 1337-1343
3. Bolla K.I., Eldreth D., Matochik J.A., and Cadet J.L. Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 26 (2005) 480-492
4. Bolla K.I., Lesage S.R., Gamaldo C.E., Neubauer D.N., Funderburk F.R., Cadet J.L., David P.M., Verdejo-Garcia A., and Benbrook A.R. Sleep disturbance in heavy marijuana users. Sleep 31 (2008) 901-908
5. Dackis C.A., Pottash A.I.C., Annitto W., and Gold M.S. Persistence of urinary marijuana levels after supervised abstinence. Am. J. Psychiatry 139 (1982) 1196-1198
6. Eldreth D., Matochik J.A., Cadet J.L., and Bolla K.I. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 23 (2004) 914-920
7. Ellis G.M., Mann M.A., Judson B.A., Schramm N.T., and Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin. Pharmacol. Ther. 38 (1985) 572-578
8. Fraser A.D., and Worth D. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol. Study III. A delta-9-THC-COOH to creatinine ratio study. Forensic Sci. Int. 137 (2003) 196-202
9. Fraser A.D., and Worth D. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV. Forensic Sci. Int. 143 (2004) 147-152
10. Herning R.I., Better W., Tate K., and Cadet J.L. EEG deficits in chronic marijuana abusers during monitored abstinence-preliminary findings. Neuroprotective Agents 993 (2003) 75-78
11. Herning R.I., Better W., Tate K., and Cadet J.L. Cerebrovascular perfusion in marijuana users during a month of monitored abstinence. Neurology 64 (2005) 488-493
12. Huestis M.A., Mitchell J.M., and Cone E.J. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J. Anal. Toxicol. 19 (1995) 443-449
13. Huestis M.A., Mitchell J.M., and Cone E.J. Urinary excretion profiles of 11-nor-9-carboxy-9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J. Anal. Toxicol. 20 (1996) 441-452
14. Huestis M.A., and Cone E.J. Urinary excretion half-life of 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. Ther. Drug Monit. 20 (1998) 570-576
15. Huestis M.A., and Cone E.J. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J. Anal. Toxicol. 22 (1998) 445-454
16. Huestis M.A., and Smith M.L. Human cannabinoid pharmacokinetics and interpretation of cannabinoid concentrations in biological fluids and tissues. In: Elsohly M. (Ed). Marijuana and the Cannabinoids (2005), Humana Press, New York 205-235
17. Hunt C.A., and Jones R.T. Tolerance and disposition of tetrahydrocannabinol in man. J. Pharmacol. Exp. Ther. 215 (1980) 35-44
18. Johansson E. Terminal elimination plasma half-life of delta-1-tetrahydrocannabinol (delta-1-THC) in heavy users of marijuana. Eur. J. Clin. Pharmacol. 37 (1989) 273-277
19. Johansson E., and Halldin M.M. Urinary excretion half-life of delta1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J. Anal. Toxicol. 13 (1989) 218-223
20. Johansson E., Gillespie H.K., and Halldin M.M. Human urinary excretion profile after smoking and oral administration of [14C] delta-1-tetrahydrocannabinol. J. Anal. Toxicol. 14 (1990) 176-180
21. Kelly P., and Jones R.T. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J. Anal. Toxicol. 16 (1992) 228-235
22. Kemp P.M., Abukhalaf I.K., Manno J.E., Manno B.R., Alford D.D., and Abusada G.A. Cannabinoids in humans. I. Analysis of delta-9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J. Anal. Toxicol. 19 (1995) 285-291
23. Kemp P.M., Abukhalaf I.K., Manno J.E., Manno B.R., Alford D.D., McWilliams M.E., Nixon F.E., Fitzgerald M.J., Reeves R.R., and Wood M.J. Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J. Anal. Toxicol. 19 (1995) 292-298
24. Lowe R.H., Karschner E.L., Schwilke E.W., Barnes A.J., and Huestis M.A. Simultaneous quantification of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC), and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A. 1163 (2007) 318-327
25. Manno J.E., Manno B.R., Kemp P.M., Alford D.D., Abukhalaf I.K., McWilliams M.E., Hagaman F.N., and Fitzgerald M.J. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta-9-tetrahydrocannabinol, 11-hydroxy-delta-9-tetrahydrocannabinol, and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid. J. Anal. Toxicol. 25 (2001) 538-549
26. Matochik J.A., Eldreth D., Cadet J.L., and Bolla K.I. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 77 (2005) 23-30
27. McBurney L.J., Bobbie B.A., and Sepp L.A. GC/MS and Emit analyses for delta-9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. J. Anal. Toxicol. 10 (1986) 56-64
28. Musshoff F., and Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther. Drug Monit. 28 (2006) 155-163
29. Peat M.A. Distribution of delta-9-tetrahydrocannabinol and its metabolites. In: Baselt R.C. (Ed). Advances in Analytical Toxicology II (1989), Year Book Medical Publishers, Chicago 186-217
30. Smith-Kielland A., Skuterud B., and Morland J. Urinary Excretion of 11-nor-9-carboxy-delta-9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J. Anal. Toxicol. 23 (1999) 323-332